9 results about "Opportunistic infection" patented technology

The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.

The invention relates to the technical field of traditional Chinese medicine extract fermentation, and provides a microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method for treating AIDS and application of microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method.The microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method comprises the steps that microspore ganoderma lucidum strains and herba houttuyniae fermentation liquor are co-fermented, beta-cyclodextrin-selenocystine of a specially-made additive is combined, and the microspore ganoderma lucidum immune protein is obtained; the problems that in traditional AIDS treatment, latent infection cells are difficult to remove, toxic and side effects of drugs are remarkable, and the reconstruction efficiency of an immune system is low are effectively solved, experiments prove that the fermentation product can activate the immune system, the cell number and the dendritic cell maturity are remarkably improved, and the curative effect is good. Meanwhile, the multi-target antiviral effect is achieved by blocking virus envelope combination, inhibiting reverse transcriptase activity and inducing latent infection cell apoptosis; the anti-oxidation and anti-inflammatory characteristics can reduce the risk of opportunistic infection, reduce the toxic damage of antiviral drugs to liver, kidney and intestinal tracts, and provide a new scheme for comprehensive treatment of AIDS and nutrition support of patients.

The present invention relates to methods for attenuating graft-versus-host disease after transplantation of a graft comprising hematopoietic stem cells in a subject. The invention further relates to methods of limiting opportunistic microbial infections in a subject after transplantation of a graft comprising hematopoietic stem cells.

The invention discloses an AIDS infection course prediction model and an establishment method thereof, and relates to the technical field of AIDS diagnosis, the prediction model comprises an AIDS combined fungal infection prediction model and an AIDS combined multi-infection prediction model; the formula of the AIDS combined fungal infection prediction model is as follows: logistic (p) =-5.838 to 0.348 * CD4 + T + 0.128 * CD8 + T + 7.329 * CD4 / CD8 + 8.236 * CD64; the formula of the AIDS combined fungal infection prediction model is as follows: logistic (p) =-0.824 to 0.182 * CD4 + T + 0.054 * CD8 + T-0. 065 * L / CD45. The established prediction model for the disease progress of the AIDS patient is helpful for further improving the definite diagnosis rate of the AIDS combined fungal infection patient and the AIDS combined multi-infection patient so as to promote the early treatment of the AIDS combined fungal infection patient and the AIDS combined multi-infection patient; meanwhile, the casualty rate of the AIDS patient caused by complications such as opportunity infection is reduced as much as possible, and a theoretical basis and a reference basis are provided for early diagnosis and precise treatment of the AIDS patient clinically.

The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.

The present invention relates to a multiplexing assay method for the quantification of BK virus (BKV) and cytomegalovirus (CMV) in a sample. According to the present invention, BKV and CMV in a sample can be simultaneously quantified by one reaction, thereby reducing inspection costs such as a reduction in the amount of the sample, a reduction in inspection time, and a reduction in inspection equipment and administration manpower. In addition, the oligonucleotide set used in the method of the present invention enables more accurate diagnosis of BKV and CMV with high sensitivity and specificity. Furthermore, the method of the present invention can increase the diagnosis rate of opportunistic infection in kidney transplanted patients and contribute to the improvement of the survival rate of transplanted organs and patients in the long term.

To provide an antibacterial functional food composition for the oral cavity that has antibacterial activity against bacteria related to periodontal and caries diseases, as well as resident bacteria that cause opportunistic infections, enables moderate saliva secretion or retention in the oral cavity during chewing, and is safe if ingested or swallowed.SOLUTION: It contains mastic as a functional ingredient.SELECTED DRAWING: None

Invasive fungal disease (IFD) constitutes an increasing health concern due to growing numbers of patients at risk for opportunistic fungal infections. Among the fungi capable of inducing opportunistic infections the yeast Candida albicans is clinically the most important. Immune evasion proteins like the pH-regulated antigen 1 (Pra1) and the translation elongation factor 1 (Tef1), which are expressed on the fungal surface and are also secreted, are major drivers of pathogenicity. Therefore, novel monoclonal antibodies (mAb) binding these proteins have been developed. In an in vivo mouse model of high-dose septic C. albicans infection, therapeutic application of mAb against Pra1 reduced clinical symptoms of the disease. Prophylactically, mAb against Tef1 protected mice from clinical disease and prolonged survival. The mABs of the present invention may also be efficacious in patients at risk or with already established IFD.

The present invention provides new bacteriophages, their selection, compositions, cocktails and formulations thereof, and their administration for the prevention of opportunistic infections in livestock, such as Avian Pathogenic E. Coli (APEC) infections in poultry.